Business

Business, Original Research

Expenditure, Utilization, and Cost of Specialty Drugs for Multiple Sclerosis in the US Medicaid Population, 2008-2018

Stakeholder Perspective

Utilization Challenges of Drugs for Multiple Sclerosis in a Medicaid Population

Business, Original Research

Association Between Formulary Coverage and Use of Abuse-Deterrent Prescription Opioids, Risk for Abuse or Overdose, and Associated Healthcare Resource Utilization

Allison Petrilla, MPH, Elizabeth Marrett, MPH, Xian Shen, PhD, MS, BS, Winghan Jacqueline Kwong, PharmD, PhD, Edmund Pezalla, MD, MPH

Stakeholder Perspective

Abuse-Deterrent Formulations of Prescription Opioids: A Missed Opportunity to Address the Current Opioid Crisis?

by Atheer A. Kaddis, PharmD

Business, Original Article

Outcomes-Based Contracting for Disease-Modifying Therapies in Multiple Sclerosis: Necessary Conditions for Paradigm Adoption

Cori Gray, PharmD, James T. Kenney, RPh, MBA

Stakeholder Perspective

Outcomes-Based Contracts Gaining Traction: Innovative Therapies Will Require Innovative Payment Methods

by Gary Branning, MBA

Business, Original Research

Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia

David Campbell, PharmD, MS, Marlo Blazer, PharmD, BCOP, Lisa Bloudek, PharmD, MS, John Brokars, MS, Dinara Makenbaeva, MD, MBA

Stakeholder Perspective

The Challenges in Budgeting Potential Savings with the Launch of Generic Drugs

by James T. Kenney, RPh, MBA

Business, Original Research

The Economic Implications of Hyperkalemia in a Medicaid Managed Care Population

Nihar R. Desai, MD, MPH, Pamala Reed, DrPH, MPH, Paula J. Alvarez, RPh, MBA, MPH, Jeanene Fogli, PhD, RD, Steven D. Woods, PharmD, Mary Kay Owens, RPh, CPh

Stakeholder Perspective

The Impact of Quality Care on a Medicaid Population with Hyperkalemia

by Byron C. Scott, MD, MBA

Business, Original Research

Differences in Patient Demographics and Healthcare Costs of Patients with PIDD Receiving Intravenous or Subcutaneous Immunoglobulin Therapies in the United States

Michael C. Runken, PharmD, Joshua M. Noone, PhD, Christopher M. Blanchette, PhD, MBA, Emily Zacherle, MS, Reuben Howden, PhD

Stakeholder Perspective

Shared Decision-Making and Payer Preferences: IVIG or SCIG Route of Administration?

by Gary M. Owens, MD

Business, Original Research

Costs and Healthcare Resource Utilization Associated with Hospital Admissions of Patients with Metastatic or Nonmetastatic Prostate Cancer

Krishna Tangirala, MPH, Sreevalsa Appukkuttan, MPH, MBBS, Stacey Simmons, MD

Stakeholder Perspective

The Challenges in Budgeting Potential Savings with the Launch of Generic Drugs

Business, Original Research

Clinical and Budget Impact of Increasing Colorectal Cancer Screening by Blood- and Stool-Based Testing

Joshua A. Roth, PhD, MHA, Theo deVos, PhD, Scott D. Ramsey, MD, PhD

Business, Original Research

Cost-Saving Opportunities with an Oral and Intravenous Once-Daily Aminomethylcycline Antibiotic for Hospitalized Patients with Community-Acquired Bacterial Pneumonia: Findings from Decision-Analytic Models

Thomas Lodise, PhD, PharmD, Kenneth LaPensee, PhD, MPH

Business, Original Research

Prevalence and Economic Burden of Epilepsy in the Institutionalized Medicare Fee-for-Service Population

Kathryn Fitch, RN, MEd, Xiaoyun Pan, MS, PhD, Jocelyn Lau, MPH, Tyler Engel, ASA, MAAA, Krithika Rajagopalan, MS, PhD

1
2
3
4

Page 1 of 14
Results 1 - 10 of 136

Copyright © Engage Healthcare Communications, LLC. All rights reserved.